|
Aursos,
Inc. a Michigan-based biotechnology company, is developing a superior implantable orthobiologic to address the rapidly growing
multibillion-dollar bone graft substitute market for bone voids, non-union fractures and spinal fusions. The company’s proprietary parathyroid hormone (PTH) peptide is the amino acid sequence
evolved by black bears that prevents bone loss despite 4-6 months of hibernation each year. Black bear
PTH (bbPTH), designated AUR84, demonstrates enhanced osteogenesis in initial preclinical models when compared to human
PTH (hPTH), which is FDA-approved for systemic use in osteoporosis (Forteo®) and under development for site-specific fracture treatment
(Kuros). Aursos is currently raising a $5M Series A to resource AUR84 preclinical safety, resorbable implant
optimization and first-in-man studies. For further information, contact Aursos President and CEO Kris Aalto at 419-517-0098.
|
